Show simple item record

dc.contributor.authorFuster, Jose J. 
dc.contributor.authorMolina-Sanchez, Pedro 
dc.contributor.authorJovaní, David
dc.contributor.authorVinué, Ángela
dc.contributor.authorSerrano, Manuel
dc.contributor.authorAndres, Vicente 
dc.date.accessioned2019-05-23T09:38:21Z
dc.date.available2019-05-23T09:38:21Z
dc.date.issued2012-03
dc.identifier.citationAtherosclerosis. 2012; 221(1):98-105es_ES
dc.identifier.issn0021-9150es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/7662
dc.description.abstractRATIONALE: Human genome-wide association studies have identified genetic variants in the chromosome 9p21 region that confer increased risk of coronary artery disease and other age-related diseases. These variants are located in a block of high linkage disequilibrium with the neighboring Ink4/Arf tumor-suppressor locus (also named CDKN2A/CDKN2B). Since previous studies suggest an atheroprotective role of the Ink4/Arf locus, here we assessed whether gain-of-function of the encoded genes can be exploited therapeutically to reduce atherosclerosis. METHODS: Generation and characterization of apolipoprotein E-null mice carrying an additional transgenic copy of the entire Ink4/Arf locus (apoE-/-Super-Ink4/Arf) that reproduces the normal expression and regulation of the endogenous locus. RESULTS: Although liver and aorta of apoE-/-Super-Ink4/Arf mice only showed a trend towards increased Ink4/Arf transcript levels compared to apoE-/- controls, cultured macrophages with increased Ink4/Arf gene dosage exhibited augmented apoptosis induced by irradiation with ultraviolet light, indicating that low level of transgene overexpression can lead to augmented Ink4/Arf function. However, increased Ink4/Arf gene dosage did not affect atherosclerosis development in different vascular regions of both male and female apoE-/- mice fed either normal or high-fat diet. Increased gene dosage of Ink4/Arf similarly had no effect on atheroma cell composition or collagen content, an index of plaque stability. CONCLUSION: In contrast with previous studies demonstrating cancer resistance in Super-Ink4/Arf mice carrying an additional transgenic copy of the entire Ink4/Arf locus, our results cast doubt on the potential of Ink4/Arf activation as a strategy for the treatment of atherosclerotic disease.es_ES
dc.description.sponsorshipThis work was supported by the Spanish Ministry of Science and Innovation (MICINN) (grant number SAF2010-16044), the Instituto de Salud Carlos III (RECAVA, grant number RD06/0014/0021), and the Dr. Léon Dumont Prize 2010 from the Belgian Society of Cardiology (to V.A.). P.M. is supported by the FPU doctoral fellowship program of the MICINN. The CNIC is supported by the MICINN and the Pro-CNIC Foundation.es_ES
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.relation.isversionofPostprintes_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subject.meshAnimals es_ES
dc.subject.meshAorta, Thoracic es_ES
dc.subject.meshAortic Diseases es_ES
dc.subject.meshApolipoproteins E es_ES
dc.subject.meshApoptosis es_ES
dc.subject.meshAtherosclerosis es_ES
dc.subject.meshCell Proliferation es_ES
dc.subject.meshCells, Cultured es_ES
dc.subject.meshCollagen es_ES
dc.subject.meshCyclin-Dependent Kinase Inhibitor p15 es_ES
dc.subject.meshCyclin-Dependent Kinase Inhibitor p16 es_ES
dc.subject.meshDiet, High-Fat es_ES
dc.subject.meshDisease Models, Animales_ES
dc.subject.meshFemale es_ES
dc.subject.meshHypercholesterolemia es_ES
dc.subject.meshLiver es_ES
dc.subject.meshMacrophages es_ES
dc.subject.meshMale es_ES
dc.subject.meshMice es_ES
dc.subject.meshMice, Inbred C57BL es_ES
dc.subject.meshMice, Knockout es_ES
dc.subject.meshMice, Transgenic es_ES
dc.subject.meshUltraviolet Rays es_ES
dc.subject.meshGene Dosage es_ES
dc.titleIncreased gene dosage of the Ink4/Arf locus does not attenuate atherosclerosis development in hypercholesterolaemic micees_ES
dc.typeArtículoes_ES
dc.rights.licenseAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.identifier.pubmedID22226369es_ES
dc.format.volume221es_ES
dc.format.number1es_ES
dc.format.page98-105es_ES
dc.identifier.doi10.1016/j.atherosclerosis.2011.12.013es_ES
dc.contributor.funderMinisterio de Ciencia e Innovación (España)es_ES
dc.contributor.funderInstituto de Salud Carlos III - ISCIIIes_ES
dc.contributor.funderBelgian Society of Cardiologyes_ES
dc.contributor.funderFundación ProCNICes_ES
dc.description.peerreviewedes_ES
dc.identifier.e-issn1879-1484es_ES
dc.relation.publisherversionhttps://doi.org/10.1016/j.atherosclerosis.2011.12.013es_ES
dc.identifier.journalAtherosclerosises_ES
dc.repisalud.orgCNICCNIC::Grupos de investigación::Fisiopatología Cardiovascular Molecular y Genéticaes_ES
dc.repisalud.institucionCNICes_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/SAF2010-16044es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/RD06/0014/0021es_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES


Files in this item

Acceso Abierto
Thumbnail
Acceso Abierto
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
This item is licensed under a: Attribution-NonCommercial-NoDerivatives 4.0 Internacional